Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion

Abstract Introduction Follicular thyroid carcinoma (FTC) includes a spectrum of neoplasms with varying propensity for metastasis. The aim of this study is to describe outcomes for FTC following multimodality treatment, with particular reference to the degree of capsular and vascular invasion and to...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology 2011-02, Vol.37 (2), p.181-185
Main Authors: O’Neill, C.J, Vaughan, L, Learoyd, D.L, Sidhu, S.B, Delbridge, L.W, Sywak, M.S
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma, Follicular
Combined Modality Therapy
Disease-Free Survival
Female
Follicular
Hematology, Oncology and Palliative Medicine
Humans
Male
Middle Aged
Neoplasm Invasiveness
Surgery
Thyroid neoplasms
Thyroid Neoplasms - pathology
Thyroid Neoplasms - therapy
Thyroid nodule
Vascular Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Follicular thyroid carcinoma (FTC) includes a spectrum of neoplasms with varying propensity for metastasis. The aim of this study is to describe outcomes for FTC following multimodality treatment, with particular reference to the degree of capsular and vascular invasion and to recommend a rational management approach based on these characteristics. Methods Patients with histologically confirmed FTC were identified from a prospectively maintained database. Details of intervention and long-term outcomes were obtained. Outcomes were compared between patients with minimally invasive follicular carcinoma (MI FTC) without vascular invasion (Group 1); angioinvasive MI FTC (Group 2); and those with widely invasive FTC (Group 3). Results Between May 1983 and December 2008, 124 patients with FTC were identified. The overall disease-free survival rate was 85% at a median of 40 months follow-up. Disease-free survival was 97%, 81% and 46%, respectively, in Groups 1, 2 and 3, and significantly different between groups ( p < 0.001). Thirteen patients in this series developed distant metastases including 2 in Group 1 and 6 in Group 2. Only patients
ISSN:0748-7983
1532-2157
DOI:10.1016/j.ejso.2010.11.005